Allogene Therapeutics (ALLO) Expected to Release Quarterly Earnings on Thursday

Allogene Therapeutics (NASDAQ:ALLO) will likely be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.1466) per share and revenue of $0.00 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.04. The business had revenue of $4.64 million during the quarter, compared to analysts’ expectations of $0.00 million. On average, analysts expect Allogene Therapeutics to post ($0.58) EPS for the current fiscal year and ($0.60) EPS for the next fiscal year.

Allogene Therapeutics Stock Performance

Shares of ALLO stock opened at $1.12 on Wednesday. Allogene Therapeutics has a 52-week low of $1.04 and a 52-week high of $4.46. The firm has a market capitalization of $386.95 million, a P/E ratio of -1.67 and a beta of 0.76. The stock has a 50 day moving average price of $1.58 and a 200 day moving average price of $1.97.

Insider Activity

In other news, CFO Geoffrey M. Parker sold 36,342 shares of the firm’s stock in a transaction that occurred on Wednesday, October 21st. The shares were sold at an average price of $1.34, for a total transaction of $48,698.28. Following the transaction, the chief financial officer directly owned 1,045,877 shares of the company’s stock, valued at approximately $1,401,475.18. This trade represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Earl Douglas sold 29,697 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $2.12, for a total transaction of $62,957.64. Following the transaction, the senior vice president directly owned 488,267 shares in the company, valued at approximately $1,035,126.04. This trade represents a 5.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 13.20% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have commented on ALLO shares. William Blair raised Allogene Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Citizens Jmp reiterated a “market outperform” rating and issued a $6.00 target price on shares of Allogene Therapeutics in a research note on Monday, August 17th. Finally, Weiss Ratings upgraded Allogene Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, October 21st. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.30.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” CAR T cell therapies for cancer. Unlike conventional autologous CAR T treatments, which are manufactured from an individual patient’s own cells, Allogene’s approach uses healthy donor cells that can potentially be produced in advance and administered more quickly.

The company’s investigational pipeline has included cemacabtagene ansegedleucel (cema-cel, formerly ALLO-501A) for certain patients with large B-cell lymphoma, as well as other allogeneic CAR T candidates being studied in blood cancers such as multiple myeloma and in solid tumors, including renal cell carcinoma.